期刊名称：CURRENT PHARMACEUTICAL DESIGN
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
Current Pharmaceutical Design publishes timely in-depth reviews covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area. An Executive editor who is an acknowledged authority in a therapeutic field has solicited for each issue comprehensive and timely reviews from leading researchers in the pharmaceutical industry and academia. Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design, including: medicinal chemistry, pharmacology, drug targets and disease mechanism. EXPANDED FREQUENCY NOW 32 ISSUES IN 2003!
Instructions to Authors
MANUSCRIPTS SUBMISSION: Authors wishing to submit comprehensive reviews in any frontier area of drug design should contact the Executive Guest Editor of the relevant field with the title and a one page summary of the proposed contents. A copy of the summary proposal should also be sent to the Journal Editor-in-Chief. Should authors wish to submit a review article in any other area of drug design not stated below, then please first submit a summary proposal to the Editor-in-Chief, William A. Banks, M.D., GRECC, Veterans Affairs Medical Center-St. Louis and Saint Louis University School of Medicine, Division of Geriatrics, Department of Internal Medicine, 915 North Grand Blvd., St. Louis, MO 63106, USA, Fax: +1 314-289-6734, e-mail: bankswa@slu.edu. Each first named author who publishes an article will receive a free one year subscription to the journal (of the current volume). The Executive Editors for the various fields are as follows: Cardiovascular and Hematological Agents. Ho-Sam Ahn, (USA), e-mail: ho-sam.ahn@spcorp.com Cardiovascular and Hematological Agents. Johann Wolfgang Auer, (Austria), e-mail: johann.auer@khwels.at COX 2 Inhibitors. Angel Lanas Arbeloa (Spain), analas@doymanet.es CNS Agents: Masato Asanuma, (Japan), e-mail: asachan@cc.okayama-u-ac.jp Anti-Infective Agents: Mitchell A. Avery/Vassil St. Georgiev, (USA), e-mail: vg8q@nih.gov The Blood Brain Barrier in Health & Disease: William A. Banks, (USA), e-mail: bankswa@slu.edu Genomics and the Prospects of Antibacterial & Antifungal Agents: John F. Barrett, (USA), e-mail: john.barrett@bms.com Anti-Infective Agents: Fatima Z. Basha/Les Mitscher, (USA), e-mail: fatima.z.basha@abbott.com Bone Disorders Drug Design and Discovery: Ren?Beerli / Martin Missbach, (Switzerland), e-mail: rene.beerli@pharma.novartis.com Anti-Cancer Drugs: E.S. Bergmann-Leitner, (USA), e-mail: esbl@helix.nih.gov Peptide Radiopharmaceuticals: Jay Elliot Blum, (USA), e-mail: peptidedoc@cox.net Anti-Angiogenesis Agents: Maurizio Botta, (Italy), e-mail: manettif@unisi.it Development of Cytokines for Use in Treatment of Blood Disorders: Ken Bradstock, (Australia), e-mail: Bradstok@icpmr.wsahs.nsw.gov.au COX-II Inhibitors: Peter Brooks, (Australia), e-mail: lineman@mailbox.uq.edu.au Kinase and Phosphatase Drug Discovery and Design. Dirksen Buzzier, (USA), e-mail: dirkson_bussiere@chiron.com Anti-Cancer Agents: Giovanni Capranico, (Italy), e-mail: giovanni.capranico@unibo.it Anti-Inflammatory and Antiallergy Agent: Tz-Chong Chou, (Taiwan), e-mail: tcchou@ms5.hinet.net Enzyme / Protease Inhibitors: Nestor Omar Concha, (USA), e-mail: Nestor_O_Concha@gsk.com Radiolabelled Compounds for Drug Discovery and Development: G.J.R. Cook, (UK), e-mail: gary.j.cook@kcl.ac.uk Anti-Thrombotics. Dermot Cox, (Ireland), e-mail: dcox@rcsi.ie Cell Biology and Chemotherapy of Trypanosomiasis and Leishmaniasis: Wanderley de Souza, (Brazil), e-mail: wsouza@sect.rj.gov.br Death Receptor Ligands: E.G. Elisabeth de Vries, (The Netherlands), e-mail: e.g.e.de.vries@int.azg.nl Antimetabolite Agents: Galal Hamza Elgemeie, (Egypt): e-mail: rughe@rusys.eg.net Neuropeptide-based Drug Design: Illana Gozes, (Israel), e-mail: igozes@post.tau.ac.il Analgesic Drug Design and Discovery: Gurmit Grewal, (USA), e-mail Gurmit.Grewal@ucb-group.com Pharmacophore Elucidation & Their Use in Drug Design. Salvatore Guccione,(Italy), e-mail: guccione@mbox.unict.it Nitric Oxide in Drug Design & Discovery: D. Hadjipavolou-Litina, (Greece), e-mail: hadjipav@pharm.auth.gr Recent Therapeutic Approaches to the Treatment of cognitive Impairment and Dementia: Bernd Ibach (Germany), e-mail: andrea.pielmeier@klinik.uni-regensburg.de Cardiovascular and Hematological Agents. Makoto Katoh, (Japan), e-mail: katoh-m@tanabe.co.jp Anti-Inflammatory and Anti-Allergy Agents: Milton John Kiefel, (Australia), e-mail: m.kiefel@mailbox.gu.edu.au Radiopharmaceuticals in Drug Discovery and Development: Michael Kassiou (Australia), e-mail: mkassiou@med.usyd.edu.au Anti-Cancer Agents: Alan P. Kozikowski / Pier Giovanni Baraldi / Maurizio Pellecchia (USA / ITALY / USA), e-mail: kozikowa@giccs.georgetown.edu / e-mail: pgb@ifeuniv.unife.it / e-mail: mpellecchia@burnham.org Antihypertensive Drugs: Gregory Y.H. Lip, (UK) G.Y.H.Lip@bham.ac.uk Cardiovascular and Hematological Agents. Eva Lonn, (Canada), e-mail: eva@ccc.mcmaster.ca Allergy-Asthma: Jan Lotvall, (Sweden), e-mail: jan.lotvall@hjl.qu.se Infectious Disease-Drug Delivery to Treat: Shigefumi Maesaki (Japan), e-mail: maesaki@saitama-med.ac.jp Angiogenesis Agents: Cezary Marcinkiewicz, (USA), e-mail: cmarcink@nimbus.ocis.temple.edu Protease Inhibitors: Robert W. Marquis, (USA), e-mail: Robert_W_Marquis@sbphrd.com Update in the Medical Treatment of Head Injured Patients in Relation to Outcome: Maria Mataro/J. Sahquillo (Spain), e-mail:mmataro@terra.es Antithrombotic Drug Design. Hiroyuki Matsuno, (Japan), e-mail: leuven@cc.gifu-u.ac.jp Applications of ACE Inhibitors and A2 Receptor Blockers: Agostino Molteni, (USA), e-mail: moltenia@umkc.edu Antihypertensive: Trefor Morgan, (Australia), e-mail: t.morgan@physiology.unimelb.edu.au Osteoporosis: Paul Morley, (Canada), e-mail: paul.morley@nrc.ca Purine Receptors as Targets for Future Drugs: Christa E. Mueller, (Germany), e-mail: christa.mueller@uni-bonn.de Anti-Cancer Agents: I. Niculescu-Duvaz, (UK), e-mail: ion@icr.ac.uk Protease Inhibitors: Vicki L. Nienaber, (USA), e-mail: vicki.nienaber@corvas.com Cytokines and Anti-cytokines: Atsushi Oda, (Japan), e-mail: aoda@med.hokudai.ac.jp DNA Topoisomerases as Targets for Anticancer Drugs: Neil Osheroff, (USA), e-mail: osheron@ctrvax.vanderbilt.edu HIV Drug Design (Anti-HIV Agents): Keykavous Parang, (USA), e-mail: kayparang@hotmail.com Tumour Selective Drug Activation: Laurence H. Patterson, (UK), e-mail: medchem@ulsop.ac.uk Bactericidal Peptides: Antonio Pellegrini, (Switzerland), e-mail: pella@vetphys.unizh.ch Drugs in Interventional Cardiology: Peter W. Radke, (Germany), e-mail: PRadke@ukaachen.de Transplantation-Anti-Rejection Agents. Markus Richter, (Germany), e-mail: drrichter@gmx.net Obesity Drug Design (Anti-Obesity Agents): J.C. Russell, (Canada), e-mail: Jim.Russell@ualberta.ca Cancer Vaccine and Immunotherapy: Farid Saleh, (Australia), e-mail: Faridslh@netscape.net Enzyme Inhibition: Michel Salzet, (France), e-mail: michel.salzet@univ-lille1.fr Cytokines: Computer Aided Design of Proteins for Therapeutic Use: Catherine H. Schein, (USA), e-mail: cathy@newton.utmb.edu G Protein-Coupled Receptor Drug Targets. Patrick Sexton, (Australia), e-mail: p.sexton@hfi.unimelb.EDU.AU Anti-Cancer Agents: Lesley Seymour, (Canada), e-mail: lseymour@ctg.queensu.ca Glutamate Receptor: Sandor Solyom (Hungary), e-mail: h13759sol@helka.iif.hu Protein MIisfolding Disorders: Claudio Soto (Switzerland) e-mail: claudio.Soto@serono.com Autoimmune Diseases: D. Stahl, (Germany), e-mail: stahld@uni-muenster.de Peptides and Peptidomimetics as Anti-cancer Therapeutics as Anti-Cancer Therapeutics: Nadya Tarasova, (USA), e-mail: tarasova@ncifcrf.gov Recent Advances in Developmental Toxicology: Gian Mario Tiboni (Italy), e-mail: tiboni@phobos.unich.it Regulatory Peptides: Nese Tuncel (Turkey), e-mail: ntuncel@ogu.edu.tr PET and SPECT in Drug Design: Aren van Waarde, (The Netherlands), e-mail: aren@pet.azg.nl Endocrine & Metabolic Agents: Allan Wagman, (USA), e-mail: allan_wagman@cc.chiron.com Antihypertensive Agents: Jiguang Wang, (Belgium), e-mail: Jiguang.Wang@med.kuleuven.ac.be Obesity Drug Design: Christian Weyer, (USA), e-mail: cweyer@amylin.com Central Nervous System Agents: Joseph Yevich/David W. Smith, (USA), e-mail: yevichj@bms.com/,e-mail: smithdw@bms.com
MANUSCRIPT PREPARATION:
The manuscript should be approximately up to 50 pages in length for full-length reviews and 30 pages for a mini-review, All pages should be numbered. Abbreviations should be defined the first time that they are used in the manuscript and a list of abbreviations used should be provided. Spelling may be in British or American but a mixture is not acceptable.
The manuscript, written in English, should be typed in double spacing throughout on A-4 or American quarto paper. Dot matrix print or any print that is difficult to read is unacceptable. Two copies of the manuscript must accompany the original (along with a passport size black and white photograph of the author and a computer disk) and should be sent to the Editor at his address. Abbreviations used should be provided. Please provide your telephone and fax numbers along with your e-mail address with all submissions to the Guest Editor.
MANUSCRIPT ORGANISATION: The manuscript should be divided as: Title page, abstract and the main text. The text may be subdivided further according to the areas to be discussed. This should be followed by the Acknowledgement (if any) and Reference sections. The first page should contain the title, the authors names (initials and surname only), with an asterisk in front of the name of the principal author.
ABSTRACT: The abstract should not exceed 250 words and it should condense the essential features of the review article, with the focus on the major advances in the field.
Key Words: Authors must supply up to eight key words along with their manuscript.
TEXT: The main text should begin on a separate page and it may be subdivided into separate sections. The review article should mention any previous important reviews in the field and contain a comprehensive discussion starting with the general background of the field. It should then go on to discuss the salient features of recent developments. The authors should avoid presenting material, which has already been published in a previous review. The reference numbers should be given in square brackets in the text. Acknowledgements should be kept to a minimum.
TABLES:
* Data Tables should be submitted in Microsoft Excel or in Microsoft Word table format.
* Each table should include a title/caption explaining what the table shows. Detailed legends may then follow.
* Tables should be given on separate pages with indications on the left hand margin to the text, as to the appropriate placement of the tables.
* Tables should not contain vertical rules.
* Columns and rows of data should be made visibly distinct by ensuring the borders of each cell display as black lines.
* Tables should be numbered consecutively in order of their citation in the body of the text, with Arabic numerals.
* If a reference is cited in both the table and text, insert a lettered footnote in the table to refer to the numbered reference in the text.
* Tabular data provided as additional files can be submitted as an Excel spreadsheet.
FIGURES / ILLUSTRATIONS:
All authors must strictly follow the guidelines below for preparing illustrations for publication in Current Pharmaceutical Design.
Editorial Requirements:
The quality of the illustrations printed in the journal largely depends on the quality of the figures/illustration provided by the author. In preparing artwork or graphics for publication, keep in mind the following points.
* Submit the original artwork or a photographic print of the original for publication.
* Do not submit photocopies. (Hardcopy submission requirement)
* Illustrations should be provided as separate files, not embedded in the text. (Hardcopy submission requirement).
* Remove all color from graphics except for those illustrations (Greyscale), which are intended to be printed in color.
* Good quality of hardcopy originals are a requirement.
* Figures/illustrations cannot be modified or enhanced by the journal production staff.
* Figures should be referred to as “Fig. (1)? “Fig. (2)?etc. in the text with figure numbers in bold within round bracket.
* Revised manuscripts should contain a complete set of artwork and photographs.
Technical Details:
* Figures should be provided on high quality, white, smooth opaque paper. (Hardcopy requirement)
Format & Resolution:
* The following file formats can be accepted. (Preference in order of appearance) : PDF, TIFF, JPEG, GIF
* Illustrations must fit a single or double column format on the journal page, according to the following guideline below:
HEIGHT
WIDTH
SINGLE COLUMN
24 cm (max)
8.5 cm (max)
DOUBLE COLUMN
24 cm (max)
18 cm (max)
* Whenever possible, submit graphics that do not have to be reduced to fit the standard figure size.
* Use the best resolution available (hardcopy submission requirement). For online submission the maximum resolution is 300 dpi.
* Avoid textures and shadings giving a three-dimensional effect to the illustration.
* Symbols and lettering in the illustration should be of similar size.
Editorial Board
Kenneth L. Audus (The University of Kansas, Lawrence, KS, USA)
Scott A. Biller (Bristol-Myers Squibb, Princeton, NJ, USA)
Steven J. Brickner (Pfizer, Groton, CT, USA)
Giovanni Capranico (Istituto Nazionale Tumori, Milan, Italy)
Craig E. Caufield (Wyeth-Ayerst Research, Princeton, NJ, USA)
Daniel T.W. Chu (Chiron Corporation, Emeryville, CA, USA)
Stevan W. Djuric (Abbott Laboratories, Abbott Park, IL, USA)
Seiji Shioda (Showa Univ. Sch. of Medicine, Shinagawa-ku, Tokyo, Japan)
Errol B. De Souza (Neurocrine Biosciences, San Diego, CA, USA)
Elisabeth G.E. De Vries (Univ. of Groningen, Groningen, Netherlands)
Annette M. Doherty (Parke-Davis, Pharm. Res. Ann Arbor, MI, USA)
Roland E. Dolle (Pharmacopeia, Inc., Princeton, NJ, USA)
Catherine L. Farrell (Amgen, Inc.,Thousand Oaks, CA, USA)
Roger M. Freidinger (Merck Res. Laboratories, West Point, PA, USA)
Donald R. Gehlert (Lilly Research Laboratories, IN, USA)
James M. Hamby (Parke-Davis, Pharm. Res. Ann Arbor, MI, USA)
Graham Johnson (Bristol-Myers Squibb, CT, USA)
Abba J. Kastin (VA Medical Center, New Orleans, LA, USA)
Keith W. Kelley (University of Illinois, Urbana, IL, USA)
Marlys Koschinsky (Queen's University, Kingston, Canada)
Hans Marquardt (Universität Hamburg, Hamburg, Germany)
Oreste A. Mascaretti (IQUIOS, Rosario, Argentina)
John H. Musser (Glycomed, Alameda, CA, USA)
Martin Petkovich (Queen's University, Kingston, Canada)
Waldemar Priebe (University of Texas, Houston, TX, USA)
Andrew V. Schally (VAMC, New Orleans, LA, USA)
George J. Schroepfer Jr. (Rice University, Houston, TX, USA)
Linus L. Shen (Abbott Laboratories, Abbott Park, IL, USA)
Jeffrey D. Shmitt (Mol. Design & IT Group, North Carolina, USA)
Nese Tuncel (Osmangazi University, Eskisehir- Turkey)
Franco Zunino (Istituto Nazionale Tumori, Milan, Italy)
|
